Rep. David Schweikert, a U.S. Congressman representing Arizona’s 1st district since 2011, recently shared a series of posts on his official social media account discussing recent healthcare developments and the influence of corporate interests in public discourse.
On March 31, 2026, Schweikert posted about meeting with representatives from AARP following a hearing by the Joint Economic Committee: “Great to see friends from @AARP after last week’s JEC hearing. Always appreciate the conversation.”
Later that day, he addressed resistance to medical innovations and telehealth initiatives: “Big hospitals were upset there was a cure for hepatitis C. They lobbied to slow it down because it threatened the infrastructure they had built around it.
Then I pushed telehealth. The people whose money depended on urgent care and ER traffic spent millions in my congressional” (March 31, 2026).
On April 1, 2026, Schweikert commented on efforts by snack food companies to influence online conversations about GLP-1 medications: “Turns out some of the biggest snack food companies were paying influencers to shut down the GLP-1 conversation.
The swamp does not stop at the Capitol anymore. It pays to shape what shows up in your feed.”
Schweikert has been an active figure in Arizona politics for decades. He first entered Congress in 2011 after replacing Harry Mitchell and previously served in the Arizona House of Representatives from 1991 to 1995. Born in Los Angeles in 1962 and currently residing in Fountain Hills, Schweikert is an alumnus of Arizona State University, where he earned degrees in both 1988 and 2005.
In recent election cycles, Schweikert secured his seat by narrow margins—defeating Jevin Hodge by less than one percent in 2022 and Amish Shah with just over half the vote in 2024.
